AEterna Zentaris to Present at Upcoming Bio Equity Europe 2006 in Frankfurt, Germany
May 16 2006 - 8:00AM
PR Newswire (US)
QUEBEC CITY, May 16 /PRNewswire-FirstCall/ -- AEterna Zentaris Inc.
(TSX: AEZ; Nasdaq: AEZS) today announced that Prof. Jurgen Engel,
Executive Vice President, Global R&D and Chief Operating
Officer of the Company, will present a corporate update at Bio
Equity Europe 2006 on Tuesday, May 23, 2006, between 11:00 a.m. and
12:15 p.m. (local time), at the Marriott Hotel in Frankfurt,
Germany. About AEterna Zentaris Inc. AEterna Zentaris Inc. is a
growing global biopharmaceutical company engaged in the discovery,
development and marketing of therapies for cancer and endocrine
disorders. AEterna Zentaris also owns 48.29% of the equity of
Atrium Biotechnologies Inc. (TSX: ATB.sv) and 64.7% of its voting
rights. Atrium is a developer, manufacturer and marketer of
science-based products for the cosmetics, pharmaceutical, chemical
and nutritional industries. News releases and additional
information are available at http://www.aeternazentaris.com/.
DATASOURCE: AETERNA ZENTARIS INC. (FORMERLY/ANCIENNEMENT - LES
LABORATOIRES AETERNA CONTACT: Media Relations: Paul Burroughs,
(418) 652-8525 ext. 406, ; Investor Relations: Jenene Thomas, (418)
655-6420 or (908) 996-3154, ; To request a free copy of this
organization's annual report, please go to http://www.newswire.ca/
and click on reports@cnw.
Copyright